References

1. Oesch, F; Arand, M. Xenobiotic Metabolism. In Toxicology; Marquardt, H., Schafer, S. G., McClellan, R., Welsch, F, Eds.; Academic Press: New York, 1999, pp 83-109.

2. Testa, B. The Metabolism of Drugs and Other Xenobiotics — Biochemistry of Redox Reactions; Academic Press: London, UK, 1995.

3. Testa, B.; Mayer, J. M. Hydrolysis in Drug and Prodrug Metabolism. Chemistry, Biochemistry and Enzymology; Verlag Helvetica Chimica Acta: Zurich, Switzerland, 2003.

4. Nelson, D. R.; Koymans, L.; Kamataki, T.; Stegeman, J. J.; Feyereisen, R.; Waxman, D. J.; Waterman, M. R.; Gotoh, O.; Coon, M. J.; Estabrook, R. W et al. Pharmacogenetics 1996, 6, 1-42.

6. Guengerich, F P Chem. Res. Toxicol. 2001, 14, 611-650.

7. Gonzalez, F J.; Lee, Y H. FASEB J. 1996, 10, 1112-1117.

8. Nebert, D. W; McKinnon, R. A. Prog. Liver Dis. 1994, 12, 63-97.

9. Coon, M. J.; Vaz, A. D. N.; Bestervelt, L. L. FASEB J. 1996, 10, 428-434.

10. Zangar, R. C.; Davydov, D. R.; Verma, S. Toxicol. Appl. Pharmacol. 2004, 199, 316-331.

11. Ioannides, C.; Lewis, D. F Curr. Top. Med. Chem. 2004, 4, 1767-1788.

12. Gonzalez, F J.; Gelboin, H. V Drug Metab. Rev. 1994, 26, 165-183.

13. Kawajiri, K.; Hayashi, S. I. The CYP1 Family. In Cytochromes P450-Metabolic and ToxicologicalAspects; Ioannides, C., Ed.; CRC Press: Boca Raton, USA, 1996, pp 77-97.

14. Fernandez-Salguero, P. M.; Gonzalez, F J. Targeted Disruption of Specific Cytochromes P450 and Xenobiotic Receptor Genes. In Cytochrome P450; Johnson, E. F, Waterman, M. R., Eds.; Academic Press: San Diego, CA, 1996; Vol. 272, pp 412-430.

15. Conney, A. H.; Chang, R. L.; Cui, X. X.; Schiltz, M.; Yagi, H.; Jerina, D. M.; Wie, S. J. Adv. Exp. Med. Biol. 2001, 500, 697-707.

16. Oesch, F Arch. Toxicol. 1979, Suppl. 2, 215-227.

17. Sogawa, K.; Matsushita, N.; Ema, M.; Fujii-Kuriyama, Y DNA-Binding Regulatory Factors and Inducible Expression of the P4501A1 Gene. In Cytochrome P450; Lechner, M. C., Ed.; John Libbey Eurotext Ltd: Montrouge, France, 1994, pp 75-80.

18. Whitlock, J. P; Okino, S. T; Dong, L. Q.; Ko, H. S. P.; Clarke-Katzenberg, R.; Qiang, M.; Li, H. FASEB J. 1996, 10, 809-818.

19. Oesch-Bartlomowicz, B.; Huelster, A.; Wiss, O.; Antoniou-Lipfert, P.; Dietrich, C.; Arand, M.; Weiss, C.; Bockamp, E.; Oesch, F Proc. Natl. Acad. Sci. USA 2005, 102, 9218-9223.

20. Raunio, H.; Rautio, A.; Pelkonen, O. IARC Sci. Publ. 1999, 148, 197-207.

21. Gervot, L.; Rochat, B.; Gautier, J. C.; Bohnenstengel, F.; Kroemer, H.; de Berardinis, V.; Martin, H.; Beaune, P.; de Waziers, I. Pharmacogenetics 1999, 9, 295-306.

22. Huang, Z.; Waxman, D. J. Cancer Gene Ther. 2001, 8, 450-458.

23. Oesch-Bartlomowicz, B.; Richter, B.; Becker, R.; Vogel, S.; Padma, P R.; Hengstler, J. G.; Oesch, F Int. J. Cancer 2001, 94, 733-742.

24. Goldstein, J. A.; de Morais, S. M. F Pharmacogenetics 1994, 4, 285-299.

25. Eichelbaum, M.; Ingelman-Sundberg, M.; Evans, W E. Annu. Rev. Med. 2006, 57, 119-137.

26. Yu, A. M.; Idle, J. R.; Gonzalez, F J. Drug Metab Rev. 2004, 36, 243-277.

27. Kessova, I.; Cederbaum, A. I. Curr. Mol. Med. 2003, 3, 509-518.

28. Ronis, M. J. J.; Lindros, K. O.; Ingelman-Sundberg, M. The CYP2E Family. In Cytochromes P450 — Metabolic and Toxicological Aspects; Ioannides, C., Ed.; CRC Press: Boca Raton, FL, 1996, pp 211-239.

29. Oesch-Bartlomowicz, B.; Padma, P R.; Becker, R.; Richter, B.; Hengstler, J. G.; Freeman, J. E.; Wolf, C. R.; Oesch, F Exp. Cell Res. 1998, 242, 294-302.

30. Maurel, P The CYP3 Family. In Cytochromes P450 — Metabolic and Toxicological Aspects; Ioannides, C., Ed.; CRC Press: Boca Raton, FL, 1996, pp 241-270.

31. Cashman, J. R. Chem. Res. Toxicol. 1995, 8, 165-181.

32. Jornvall, H.; Hoog, J. Alcohol Alcoholism 1995, 30, 153-161.

33. Glatt, H. R.; Vogel, K.; Bentley, P; Oesch, F Nature 1979, 277, 319-320.

34. Glatt, H. R.; Cooper, C. S.; Grover, P L.; Sims, P.; Bentley, P; Merdes, M.; Waechter, F; Vogel, K.; Guenthner, T. M.; Oesch, F Science 1982, 215, 1507-1509.

35. Worner, W; Oesch, F FEBS Lett. 1984, 170, 263-267.

36. Maser, E.; Richter, E.; Friebertshauser, J. Eur. J. Biochem. 1996, 238, 484-489.

37. Wermuth, B.; Platt, K. L.; Seidel, A.; Oesch, F Biochem. Pharmacol. 1986, 35, 1277-1282.

38. Arand, M.; Oesch, F Mammalian Xenobiotic Epoxide Hydrolases. In Handbook of Enzyme Systems that Metabolize Drugs and Other Xenobiotics; Ioannides, C., Ed.; John Wiley: Chichester, UK, 2002, pp 459-483.

41. Guenthner, T M.; Hammock, B. D.; Vogel, U.; Oesch, F J. Biol. Chem. 1981, 256, 3163-3166.

42. Morisseau, C.; Hammock, B. D. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 311-333.

43. Arand, M.; Grant, D. F; Beetham, J. K.; Friedberg, T.; Oesch, F; Hammock, B. D. FEBS Lett. 1994, 338, 251-256.

44. Armstrong, R. N. CRC Crit. Rev. Biochem. 1987, 22, 39-88.

45. Arand, M.; Wagner, H.; Oesch, F J. Biol. Chem. 1996, 271, 4223-4229.

46. Oesch, F; Herrero, M. E.; Hengstler, J. G.; Lohmann, M.; Arand, M. Toxicol. Pathol. 2000, 28, 382-387.

47. Herrero, M. E.; Arand, M.; Hengstler, J. G.; Oesch, F Environ. Mol. Mutagen 1997, 30, 429-439.

48. Armstrong, R. N. Chem. Res. Toxicol. 1991, 4, 131-140.

49. Glatt, H.; Protic-Sabljic, M.; Oesch, F Science 1983, 220, 961-963.

50. Dekant, W; Vamvakas, S. Crit. Rev. Toxicol. 1996, 26, 309-334.

51. Chen, H. W; Sandler, D. P.; Taylor, J. A.; Shore, D. L.; Liu, E.; Bloomfield, C. D.; Bell, D. A. Lancet 1996, 347, 295-297.

52. Burchell, B.; McGurk, K.; Brierley, C. H.; Clarke, D. J. UDP-Glucuronosyltransferases. In Comprehensive Toxicology; Guengerich, F P., Ed.; Elsevier: Amsterdam, Netherlands, 1997; Vol. 3, pp 401-435.

53. Bock, K. W Crit. Rev Biochem. Mol. Biol. 1991, 26, 129-150.

54. Owens, I. S.; Ritter, J. K. Gene Structure at the Human UGT1 Locus Creates Diversity in Isozyme Structure, Substrate Specificity and Regulation. In Progress in Nucleic Acid Research and Molecular Biology; Cohn, W E., Moldave, K., Eds.; Academic Press: San Diego, CA, 1995; Vol. 51, pp 305-338.

55. Glatt, H. R. Sulphotransferases. In Handbook of Enzyme Systems that Metabolise Drugs and Other Xenobiotics; Ioannides, C., Ed.; John Wiley: Chichester, UK, 2002, pp 353-439.

56. Coughtrie, M. W H. Hum. Exp. Toxicol. 1996, 15, 547-555.

57. Goodfellow, G. H.; Dupret, J. M.; Grant, D. M. Biochem J 2000, 348, 159-166.

58. Badawi, A. F; Stern, S. J.; Lang, N. P.; Kadlubar, F F Prog. Clin. Biol. Res. 1996, 395, 109-140.

59. Vistisen, K.; Poulsen, H. E.; Loft, S. Carcinogenesis 1992, 13, 1561-1568.

60. Morgan, E. T.; Thomas, K. B.; Swanson, R.; Vales, T; Hwang, J.; Wright, K. Biochim. Biophys. Acta 1994, 1219, 475-483.

61. Nebert, D. W; McKinnon, R. A.; Puga, A. DNA Cell Biol. 1996, 15, 273-280.

62. Smith, C. A. D.; Smith, G.; Wolf, C. R. Eur. J. Cancer 1994, 30A, 1921-1935.

63. Meyer, U. A.; Zanger, U. M. Annu. Rev. Pharmacol. Toxicol. 1997, 37, 269-296.

64. Hengstler, J. G.; Arand, M.; Herrero, M. E.; Oesch, F Recent Results Cancer Res. 1998, 154, 47-85.

65. Ingelman-Sundberg, M. Toxicology 2002, 181-182, 447-452.

66. Brockmoller, J.; Cascorbi, I.; Kerb, R.; Roots, I. Cancer Res. 1996, 56, 3915-3925.

67. Wormhoudt, L. W; Commandeur, J. N.; Vermeulen, N. P. Crit. Rev. Toxicol. 1999, 29, 59-124.

68. Hengstler, J. G.; Oesch, F Interspecies Differences inXenobiotic Metabolizing Enzymes and their Importance for Interspecies Extrapolation of Toxicity. In General and Applied Toxicology; Ballantyne, B., Marrs, T C., Syversen, T, Eds.; Macmillan: London, 1999, pp 271-290.

69. Turesky, R. J. Mol. Nutr. Food Res. 2005, 49, 101-117.

70. Utesch, D.; Glatt, H.; Oesch, F Cancer Res. 1987, 47, 1509-1515.

71. Hengstler, J. G.; Utesch, D.; Steinberg, P.; Platt, K. L.; Diener, M.; Ringel, M.; Swales, N.; Fischer, T.; Biefang, K.; Gerl, M. et al. DrugMetab. Rev. 2000, 32, 81-118.

72. Gonzalez, F J.; Yu, A. M. Annu. Rev. Pharmacol. Toxicol. 2006, 46, 41-64.

73. Buening, M. K.; Wislocki, P G.; Levin, W; Yagi, H.; Thakker, D. R.; Akagi, H.; Koreeda, M.; Jerina, D. M.; Conney, A. H. Proc. Natl. Acad. Sci. USA 1978, 75, 5358-5361.

Biographies

Barbara Oesch Bartlomowicz

Barbara Oesch-Bartlomowicz passed her Medical State Examination at the Pommeranian Medical Academy, Szczecin, Poland in 1978, and was awarded her License to Practice Medicine in 1979. In 1981 she was a Visiting Scientist at the Institute for Biocatalysis, Academy of Sciences, Berlin-Buch, Germany. She was awarded her MD degree in 1983 by the Pommeranian Medical Academy, Szczecin, Poland where she obtained her License in 1984 as a specialist in Pharmacology and Toxicology and as a specialist in Dermatology. In 1987 she was a Visiting Scientist at the Institute of Toxicology, University of Mainz, Germany. Between 1988 and 1989 she was a Scholar of the European Science Foundation. In 1989 she became a Research Associate at the Institute of Toxicology, University of Mainz, Germany, becoming a University Assistant in 1994. In 1999 she was nominated Professor of Pharmacology and Toxicology. In 1996 she was a visiting scientist at the Department of Environmental Toxicology, University of California, Davis, USA. Professor Oesch-Bartlomowicz is currently University Docent, Institute of Toxicology, University of Mainz.

Franz Oesch obtained a PhD from the University of Fribourg, Switzerland in 1969. In 1973 he became Privatdozent at the University of Basel, Switzerland. Between 1974 and 1981 he was Professor (C3) of Pharmacology and Toxicology and Head of Section for Molecular Pharmacology at the University of Mainz, Germany. From 1981 on he was Professor

(C4) of Pharmacology and Toxicology initially (1981-1983) as Chairman of the Department of Molecular Pharmacology, then (from 1983 on) as Director of the Institute of Toxicology, University of Mainz.

Professor Oesch has been awarded the following prizes:

Professor Max Cloetta Prize 1977; American Society of Pharmacology and Experimental Therapeutics Award for the best publication of 1980 in Drug Metabolism and Disposition; Robert Koch Prize 1982; GUM Prize of the Environmental Mutagen Society 1985; Prize of the Rheinisch-Westfalische Academy of Sciences 1989; German Cancer Price 1990; Hoechst-Marion-Roussel-Price 1998; and Prize for Scientific Innovation of the State Rheinland-Pfalz 1999. Other honors include: Most Quoted Scientists: belonging to the top 0.1% (Current Contents No. 41, October 12, 1981); Keynote Lecture, International ISSX Meeting, Amsterdam, 1991; Otto Warburg Memorial Lecture, Berlin, 1992; Election to the Academia Europea, 1992; Keynote Review, International EAPCCT Congress, Zürich, 1998; Keynote Lecture, European Workshop on Drug Metabolism, Kopenhagen, 1998; The Gerhard Zbinden Memorial Lecture Award, EUROTOX, London, 2000; and Werner Heisenberg-Medaille, 2000.

© 2007 Elsevier Ltd. All Rights Reserved Comprehensive Medidnal Chemistry II

No part of this publication may be reproduced, stored in any retrieval system or transmitted ISBN (set): 0-08-044513-6 in any form by any means electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the publishers ISBN (Volume 5) 0-08-044518-7; pp. 193-214

Was this article helpful?

0 0
Lower Your Cholesterol In Just 33 Days

Lower Your Cholesterol In Just 33 Days

Discover secrets, myths, truths, lies and strategies for dealing effectively with cholesterol, now and forever! Uncover techniques, remedies and alternative for lowering your cholesterol quickly and significantly in just ONE MONTH! Find insights into the screenings, meanings and numbers involved in lowering cholesterol and the implications, consideration it has for your lifestyle and future!

Get My Free Ebook


Post a comment